Clinical trial
Safety and Antiviral Activity of Clevudine in Patients Who Have Completed the…
NCT00362505 · Bukwang Pharmaceutical, Industry · Terminated
Key facts
| NCT number | NCT00362505 |
|---|---|
| Title | Safety and Antiviral Activity of Clevudine in Patients Who Have Completed the L-FMAU-301 or L-FMAU-302 Trials |
| Official title | An Open-label, Phase III Clinical Trial to Evaluate the Safety and Antiviral Activity of Clevudine in Chronic Hepatitis B Patients Who Have Completed the L-FMAU-301 or L-FMAU-302 Trials |
| Lead sponsor | Bukwang Pharmaceutical, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis B |
| Intervention type | Drug |
| Interventions | Clevudine |
| Start date | Jun 1, 2004 |
| Completion | Mar 1, 2006 |
| First posted | Aug 10, 2006 |
| Last update posted | Feb 1, 2017 |
| Countries | South Korea |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: